CryoLife is one of the world’s contemporary medical device companies providing preserved human cardiac and vascular tissues, surgical adhesives and sealants, cardiac lasers and implantable end-stage renal disease access grafts for the repair of complex cardiac and vascular reconstruction surgeries.

CryoLife using its proprietary SynerGraft technology processes the CryoValve SG pulmonary heart valve and CryoPatch SG pulmonary cardiac patch. CryoLife’s CardioGenesis specializes in the treatment of severe angina using a laser console system and fiber-optic handpieces to perform a surgical procedure known as Transmyocardial Revascularization (TMR). CryoLife markets the HeRO Graft, which provides vascular access for hemodialysis patients. CryoLife distributes PerClot, an absorbable powdered hemostat, in international markets. CryoLife’s BioFoam Surgical Matrix is CE marked in the European Community for use as an adjunct to hemostasis.

CryoLife was founded in 1984 and is headquartered in Kennesaw, US

Member of the Board

CryoLife has offices in Kennesaw, Guildford, Freiburg im Breisgau, Singapore and in 1 other location

Kennesaw, US (HQ)

1655 Roberts Blvd

Paris, FR

52 Rue de la Victoire

Singapore, SG

1 Marina Blvd

Freiburg im Breisgau, DE

19 Engelbergerstraße

Guildford, GB

Old Portsmouth Rd

CryoLife's revenue was reported to be $45.1 m in Q1, 2017

USD

## Revenue (Q1, 2017) | 45.1 m |

## Net income (Q1, 2017) | 2.2 m |

## EBIT (Q1, 2017) | 2.5 m |

## Market capitalization (17-Aug-2017) | 642.5 m |

## Cash (31-Mar-2017) | 58.9 m |

CryoLife's current market capitalization is $642.5 m.

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Revenue | 140.8 m | 144.6 m | 145.9 m | 180.4 m |

## Revenue growth, % | 3% | 1% | 24% | |

## Gross profit | 90.4 m | 91.3 m | 90.7 m | |

## Gross profit Margin, % | 64% | 63% | 62% | |

## R&D expense | 13.4 m | |||

## Operating expense total | 76.6 m | 82.5 m | 85.4 m | 105 m |

## EBIT | 13.8 m | 8.8 m | 5.4 m | 21.8 m |

## EBIT margin, % | 10% | 6% | 4% | 12% |

## Interest expense | 175 k | 62 k | 3 m | |

## Interest income | 50 k | 45 k | 72 k | |

## Pre tax profit | 8.7 m | 5.9 m | 18.4 m | |

## Income tax expense | 1.4 m | 1.9 m | 7.6 m | |

## Net Income | 16.2 m | 7.3 m | 4 m | 10.8 m |

USD | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|

## Revenue | 43 m | 47.1 b | 45.3 m | 45.1 m |

## R&D expense | 2.6 m | 3.3 b | 3.7 m | 4.1 m |

## Operating expense total | 2.6 m | 3.3 b | 3.7 m | 4.1 m |

## EBIT | 6.7 m | 4.6 b | 5.5 m | 2.5 m |

## EBIT margin, % | 15% | 10% | 12% | 6% |

## Interest expense | 717 k | 797 m | 742 k | 801 k |

## Interest income | (12 k) | (18 m) | (18 k) | (40 k) |

## Pre tax profit | 6.1 m | 3.9 b | 4.7 m | 1.7 m |

## Income tax expense | 3.5 m | 1.5 b | 1.7 m | (479 k) |

## Net Income | 2.5 m | 4.9 m | 7.9 m | 2.2 m |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Cash | 37.6 m | 33.4 m | 37.6 m | 56.6 m |

## Accounts Receivable | 136.7 m | |||

## Inventories | 9.8 m | 12.7 m | 14.6 m | 26.3 m |

## Current Assets | 106.3 m | 106 m | 109.7 m | 147.2 m |

## Goodwill | 11.4 m | 11.4 m | 11.4 m | 78.3 m |

## Total Assets | 174.7 m | 176.2 m | 181.2 m | 316.1 m |

## Accounts Payable | 4.1 m | 4.5 m | 4.6 m | 5.7 m |

## Total Debt | 71.6 m | |||

## Current Liabilities | 20.7 m | 20.6 m | 19.6 m | 30.1 m |

## Total Liabilities | 107.2 m | |||

## Additional Paid-in Capital | 128.6 m | 135.2 m | 142.9 m | 187.1 m |

## Retained Earnings | 18.7 m | 22.8 m | 23.4 m | 34.1 m |

## Total Equity | 144.7 m | 148.7 m | 155.3 m | 209 m |

## Debt to Equity Ratio | 0.3 x | |||

## Debt to Assets Ratio | 0.2 x | |||

## Financial Leverage | 1.2 x | 1.2 x | 1.2 x | 1.5 x |

USD | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|

## Cash | 44.8 m | 46.9 m | 54.1 m | 58.9 m |

## Inventories | 25.3 m | 25.4 m | 25.5 m | 25.8 m |

## Current Assets | 129.2 m | 135.8 m | 142.1 m | 149.2 m |

## PP&E | 16.5 m | 16.4 m | 17.2 m | 20.2 m |

## Goodwill | 76.8 m | 76.8 m | 76.5 m | 78.3 m |

## Total Assets | 297.2 m | 303 m | 308.9 m | 319.4 m |

## Accounts Payable | 5.6 m | 5.2 m | 5.7 m | 7.3 m |

## Current Liabilities | 24.8 m | 24.7 m | 24.8 m | 28.1 m |

## Common Stock | 339 k | 341 k | 342 k | 346 k |

## Additional Paid-in Capital | 180.2 m | 182.1 m | 185.2 m | 189.9 m |

## Retained Earnings | 25.9 m | 28.3 m | 31.2 m | 36.1 m |

## Total Equity | 194.2 m | 198.1 m | 204.2 m | 213.4 m |

## Financial Leverage | 1.5 x | 1.5 x | 1.5 x | 1.5 x |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Net Income | 16.2 m | 7.3 m | 4 b | 10.8 m |

## Depreciation and Amortization | 5.8 m | 6 m | 5.9 b | 8.4 m |

## Cash From Operating Activities | 24.6 m | (4.3 m) | 4.2 m | |

## Capital Expenditures | (4.3 m) | (4.3 m) | (3.5 b) | (6.2 m) |

## Cash From Investing Activities | (73.9 m) | |||

## Dividends Paid | (3 m) | (3.3 m) | (3.4 b) | (3.4 m) |

## Cash From Financing Activities | (3.1 m) | (7 m) | (2.8 b) |

USD | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|

## Net Income | 2.5 m | 4.9 m | 7.9 m | 2.2 m |

## Depreciation and Amortization | 1.9 m | 4.1 m | 6.2 m | 2.2 m |

## Capital Expenditures | (820 k) | (1.6 m) | (3.5 m) | (2 m) |

## Cash From Investing Activities | (67.2 m) | (69.2 m) | (71.1 m) | (1.2 m) |

## Dividends Paid | (850 k) | (1.7 m) | (2.6 m) |

USD | Y, 2017 |
---|---|

## Revenue/Employee | 67.8 k |

## Financial Leverage | 1.5 x |